Celltrion Keeps Pace With Ustekinumab Rivals
Moves CT-P43 Stelara Biosimilar Into Phase III Trials
Executive Summary
Celltrion is looking to keep its ustekinumab biosimilar program in step with those of rival developers, after announcing the start of Phase III trials for its CT-P43 candidate.
You may also be interested in...
Celltrion Is Latest To Settle Over Stelara
Celltrion has become the latest biosimilars developer to announce a deal with J&J allowing it to launch a US ustekinumab biosimilar in early 2025. The Korean firm anticipates US FDA approval next year for its CT-P43 version.
History Repeating: Will US Stelara Settlements Follow Humira’s Lead?
Years before Humira rivals hit the US market in 2023, a series of litigation settlements between biosimilar adalimumab developers and originator AbbVie provided a roadmap for a succession of date-certain launches this year. Now, similar settlements over Stelara between J&J and ustekinumab developers are starting to fall into place for 2025.
Celltrion Eyes Price Advantage For ‘Latecomer’ Bevacizumab
Celltrion has indicated that it intends to leverage its ability to compete on cost to gain a foothold in the bevacizumab market, despite being a “latecomer” in the wake of firms that have previously launched and filed biosimilar rivals to Avastin.